Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
INSY's Cash to Debt is ranked higher than
87% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. INSY: No Debt )
INSY' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.77
INSY's Equity to Asset is ranked higher than
80% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INSY: 0.77 )
INSY' s 10-Year Equity to Asset Range
Min: -3.45   Max: 0.98
Current: 0.77

-3.45
0.98
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
68% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: No Debt )
INSY' s 10-Year Interest Coverage Range
Min: 35.09   Max: 9999.99
Current: No Debt

35.09
9999.99
F-Score: 4
Z-Score: 24.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 31.81
INSY's Operating margin (%) is ranked higher than
96% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. INSY: 31.81 )
INSY' s 10-Year Operating margin (%) Range
Min: -324863.64   Max: 56.36
Current: 31.81

-324863.64
56.36
Net-margin (%) 26.93
INSY's Net-margin (%) is ranked higher than
95% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. INSY: 26.93 )
INSY' s 10-Year Net-margin (%) Range
Min: -301890.91   Max: 40.67
Current: 26.93

-301890.91
40.67
ROE (%) 53.71
INSY's ROE (%) is ranked higher than
98% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. INSY: 53.71 )
INSY' s 10-Year ROE (%) Range
Min: -223.53   Max: 545.67
Current: 53.71

-223.53
545.67
ROA (%) 42.06
INSY's ROA (%) is ranked higher than
99% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. INSY: 42.06 )
INSY' s 10-Year ROA (%) Range
Min: -566.67   Max: 67.69
Current: 42.06

-566.67
67.69
ROC (Joel Greenblatt) (%) 197.84
INSY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. INSY: 197.84 )
INSY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2087.93   Max: 775
Current: 197.84

-2087.93
775
Revenue Growth (%) 457.20
INSY's Revenue Growth (%) is ranked higher than
100% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. INSY: 457.20 )
INSY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 457.2
Current: 457.2

0
457.2
» INSY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

INSY Guru Trades in Q4 2013

Joel Greenblatt 16,108 sh (New)
Steven Cohen Sold Out
Chuck Royce Sold Out
Jim Simons Sold Out
» More
Q1 2014

INSY Guru Trades in Q1 2014

Jim Simons 137,080 sh (New)
Steven Cohen 9,088 sh (New)
Joel Greenblatt 16,982 sh (-29.72%)
» More
Q2 2014

INSY Guru Trades in Q2 2014

Paul Tudor Jones 17,626 sh (New)
Joel Greenblatt 30,111 sh (+77.31%)
Steven Cohen 168,700 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

INSY Guru Trades in Q3 2014

Chase Coleman 300,000 sh (New)
Steven Cohen 675,765 sh (+300.57%)
Paul Tudor Jones 22,394 sh (+27.05%)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.01%$24.45 - $39.3 $ 46.6949%0
Joel Greenblatt 2014-06-30 Add 77.31%0.01%$22.6 - $42.93 $ 46.6944%30111
Joel Greenblatt 2014-03-31 Reduce -29.72%$25.807 - $55.58 $ 46.6919%16982
Joel Greenblatt 2013-12-31 New Buy0.02%$24.01 - $32.72 $ 46.6968%16108
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 32.90
INSY's P/E(ttm) is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 32.90 )
INSY' s 10-Year P/E(ttm) Range
Min: 17.67   Max: 2102.36
Current: 32.9

17.67
2102.36
P/B 10.90
INSY's P/B is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. INSY: 10.90 )
INSY' s 10-Year P/B Range
Min: 0.05   Max: 19.89
Current: 10.9

0.05
19.89
P/S 8.70
INSY's P/S is ranked higher than
85% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. INSY: 8.70 )
INSY' s 10-Year P/S Range
Min: 1.74   Max: 45119.95
Current: 8.7

1.74
45119.95
PFCF 64.80
INSY's PFCF is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 64.80 )
INSY' s 10-Year PFCF Range
Min: 29.42   Max: 173.14
Current: 64.8

29.42
173.14
EV-to-EBIT 24.79
INSY's EV-to-EBIT is ranked higher than
95% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 24.79 )
INSY' s 10-Year EV-to-EBIT Range
Min: -83.2   Max: 103.5
Current: 24.79

-83.2
103.5
Current Ratio 2.98
INSY's Current Ratio is ranked higher than
65% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. INSY: 2.98 )
INSY' s 10-Year Current Ratio Range
Min: 0.14   Max: 318.82
Current: 2.98

0.14
318.82
Quick Ratio 2.25
INSY's Quick Ratio is ranked higher than
63% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. INSY: 2.25 )
INSY' s 10-Year Quick Ratio Range
Min: 0.06   Max: 318.82
Current: 2.25

0.06
318.82

Valuation & Return

vs
industry
vs
history
Price/Net Cash 81.90
INSY's Price/Net Cash is ranked higher than
73% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. INSY: 81.90 )
INSY' s 10-Year Price/Net Cash Range
Min: 1   Max: 72.07
Current: 81.9

1
72.07
Price/Net Current Asset Value 28.60
INSY's Price/Net Current Asset Value is ranked higher than
74% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. INSY: 28.60 )
INSY' s 10-Year Price/Net Current Asset Value Range
Min: 1   Max: 72.07
Current: 28.6

1
72.07
Price/Tangible Book 11.10
INSY's Price/Tangible Book is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. INSY: 11.10 )
INSY' s 10-Year Price/Tangible Book Range
Min: 0.62   Max: 105.92
Current: 11.1

0.62
105.92
Price/DCF (Projected) 34.30
INSY's Price/DCF (Projected) is ranked higher than
91% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 34.30 )
INSY' s 10-Year Price/DCF (Projected) Range
Min: 2.09   Max: 86.75
Current: 34.3

2.09
86.75
Price/Graham Number 3.90
INSY's Price/Graham Number is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 3.90 )
INSY' s 10-Year Price/Graham Number Range
Min: 2.84   Max: 8.62
Current: 3.9

2.84
8.62
Earnings Yield (Greenblatt) 4.10
INSY's Earnings Yield (Greenblatt) is ranked higher than
94% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. INSY: 4.10 )
INSY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 3669.5
Current: 4.1

1
3669.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPR1.Germany,
Insys Therapeutics Inc was incorporated in Delaware in June 1990. The Company is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products. The Company has two marketed products Subsys and Dronabinol SG Capsule. Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. It markets Subsys through an incentive-based sales model. Dronabinol SG Capsule is a dronabinol soft gelatin capsule that is a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS, offered in 2.5, 5.0 and 10.0 milligram dosages. The Company produces the Active Pharmaceutical Ingredient (API) for Dronabinol SG Capsule at its U.S.-based, state-of-the-art dronabinol manufacturing facility. The Company is subject to regulation by the FDA.
» More Articles for INSY

Headlines

Articles On GuruFocus.com
Insys Therapeutics Receives FDA Orphan Drug Designation for Liposome Entrapped Paclitaxel as a Poten Dec 09 2014 
Parallel Comparison Analyses Confirm That Insys Therapeutics' Synthetic CBD Is Identical in Chemical Dec 04 2014 
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Pote Nov 24 2014 
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Pote Oct 15 2014 

More From Other Websites
Stocks Hold Near Session Highs; FedEx Bounces Back Dec 18 2014
Nasdaq stocks posting largest percentage increases Dec 18 2014
Insys Therapeutics Receives FDA Orphan Drug Designation for Liposome Entrapped Paclitaxel as a... Dec 09 2014
Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point Dec 08 2014
A Drug Maker Uses Doctors With Troubled Pasts to Promote a Painkiller Dec 02 2014
Insys' Cannabidiol Gets another Orphan Drug Designation Nov 25 2014
Cardica (CRDC) in Focus: Stock Moves Up 8.7% in Session Nov 24 2014
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a... Nov 24 2014
Insys Therapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference Nov 19 2014
INSYS THERAPEUTICS, INC. Financials Nov 19 2014
The most dangerous medical marijuana myth Nov 15 2014
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 14 2014
Insys Therapeutics (INSY) Is Weak On High Volume Today Nov 12 2014
Insys Therapeutics downgraded by Oppenheimer Nov 12 2014
INSYS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 12 2014
INSYS Therapeutics (INSY) in Focus: Stock Rises 12% Nov 12 2014
Dow, S&P 500 close at record on Veterans Day Nov 11 2014
Insys Q3 Beats Estimates, Helping Stock Rebound Nov 11 2014
Insys Therapeutics (INSY) Stock Soars Today on Third Quarter Earnings Beat Nov 11 2014
US stock futures add to gains; D.R. Horton reports Nov 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK